Navigation Links
EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study
Date:10/18/2011

ts to new RNA-based companion diagnostics that result from the trial but research using biological samples / clinical data is open to the entire scientific community.

About MINDACT

Coordinated by the European Organisation for Research and Treatment of Cancer (EORTC) and run under the BIG/TRANSBIG networks, MINDACT aims to provide confirmatory evidence that patients with a low recurrence risk signature by Mammaprint® may be spared chemotherapy and its burdensome side effects, without negative repercussions on survival rate. MINDACT, which involved sites in the Netherlands, France, Germany, Belgium, Spain, Italy, UK, Slovenia, and Switzerland, began recruiting patients in 2007 and its first results are expected in approximately three years.

Ancillary research is led by TRANSBIG, a consortium launched by BIG (Breast International Group) in 2004 and supported by the European Union's 6th Framework Program to promote international collaboration in translational research. Further research grants have been received from the Breast Cancer Research Foundation, Novartis, F. Hoffman La Roche, Sanofi-Aventis, the National Cancer Institute (NCI), the EBCC-Breast Cancer Working Group, the Jacqueline Seroussi Memorial Foundation, Prix Mois du Cancer du Sein, Susan G. Komen for the Cure, Fondation Belge Contre le Cancer, Dutch Cancer Society (KWF), Association Le Cancer du Sein, Parlons-en!, Deutsche Krebshilfe and the Grant Simpson Trust and Cancer Research UK. Whole genome analysis is provided in kind by Agendia.

This trial would not have been possible without such support and the collaboration of hundreds of healthcare professionals across multiple disciplines, and above all without the trust and participation of all the patients.

For more information on MINDACT please visit:

http://www.breastinternationalgroup.org/Publications/MINDACTBroch
'/>"/>

SOURCE Agendia B.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Agendia Successfully Completes Bi-Annual FDA Inspection
2. Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
3. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
4. Medicare Administrator Establishes Reimbursement Coding Policy for Agendias Breast Cancer Recurrence Test MammaPrint(R)
5. Agendia Raises US $23 Million in Series E Financing
6. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
7. Agendia Opens CLIA-Registered U.S. Genomics Laboratory
8. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
9. Agendia to Present at BioCenturys Future Leaders in the Biotech Industry Conference
10. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
11. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/29/2015)... 2015 Sanofi, a global ... second quarter of 2015. CEO Olivier Brandicourt ... performance in different businesses. Watch video ... Topics covered in the interview ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... Japan (Q2 2015: +14% CER / 20% of sales) ... in China , as well as solid contributions from Korea, ... Europe / Middle East / ... in Germany , Turkey and the ... 49% of sales) grew 11%, excluding U.S. HPV sales, on demand across all ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10
... ISIS ) announces the following webcast: , , ... of a, microRNA, ... 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT, Where: ... Simply log onto our website listed above., , ...
... in the research of vein treatment methods led by Dr. Sinjae Hyun, ... new medical device, which he will present this summer to his research ... ... A gift from a California company aided in the research of ...
... Dec. 1 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... and Drug,Administration (FDA) has accepted for filing and ... supplemental Biologics License Application,(sBLA) for use of Zevalin(R) ... B-cell non-Hodgkin,s lymphoma who achieve,a response to first-line ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... search for better ways to target anticancer drugs to ... nanoparticles called buckyballs might be used to significantly boost ... In research due to appear in an upcoming issue ... and The University of Texas M. D. Anderson Cancer ...
... the National Institute of Standards and Technology (NIST) have ... for small numbers of biomolecules. The unusually simple containment ... and perhaps lead to the development of molecule-sorting devices ... research. The work was reported in the July 3 ...
... world soon could be made completely flood-tolerant because ... in collaboration with scientists at UC Davis and ... By gradually introducing into California rice "submergence tolerance," ... flood conditions, the researchers show how potentially any ...
Cached Biology News:Buckyballs boost antibody's chemotherapy payload 2'Micro-boxes' of water used to study single molecules 2Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3
... The potential applications for the use of ... gene expression via the RNA interference (RNAi) ... cellular and molecular biology fields. siRNA for ... either chemically or enzymatically, and then transfected ...
... applications for the use of small interfering ... via the RNA interference,(RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... and then transfected into the target cells ...
... HybArray 12™ is an automated hybridization system ... system automates both the hybridization and post ... slides. A single instrument can process up ... pairs and has multi-protocol software, enabling the ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
Biology Products: